EFFECTIVE SENSITIZING DOSE OF A GELLED IMMUNOMODULATING TOPICAL COMPOSITION
The present invention relates to compositions and methods of treating warts and other human papilloma virus (HPV) skin infections. The present invention relates to compositions and methods of treating skin cancer.
1 . A method of treating a disease or disorder associated with human papilloma virus infection in a human patient, the method comprising administering to a first site on the skin of a human patient a low sensitizing dose of an immunomodulating gel composition followed by a subsequent administration to a second site on the skin of said patient a challenge dose of said immunomodulating gel composition, wherein said composition comprises diphenylcyclopropenone (DPCP).
2 . The method of claim 1 , wherein said disease or disorder associated with human papilloma virus infection is selected from the group consisting of common warts, plantar warts, inguinal warts, venereal warts, and any combination thereof.
3 . The method of claim 1 , wherein said low sensitizing dose is in the range of about 0.4% (w/w) DPCP to about 0.6% (w/w) DPCP, and wherein said challenge dose is in the range of about 0.04% (w/w) DPCP to about 0.1% (w/w) DPCP.
4 . The method of claim 1 , wherein said low sensitizing dose is about 0.4% (w/w) DPCP, and wherein said challenge dose is about 0.04% (w/w) DPCP.
5 . The method of claim 1 , wherein a subsequent challenge dose is administered to the skin of said patient daily.
6 . The method of claim 1 , wherein a subsequent challenge dose is administered to the skin of said patient every other day.
7 . The method of claim 1 , wherein a subsequent challenge dose is administered to the skin of said patient biweekly.
8 . The method of claim 1 , wherein a subsequent challenge dose is administered to the skin of said patient weekly.
9 . The method of claim 1 , wherein said immunomodulating gel composition further comprises a gel delivery system comprising: a) a first co-solvent comprising a non-ionic surfactant, b) a second co-solvent comprising an alcoholic ester, and c) a gelling agent.
10 . The method of claim 9 , wherein said first co-solvent is selected from the group consisting of polyoxyethylene (20) monoleate, polyoxyethylene (20) sorbitan monooleate, palmitate and stearate, and wherein said second co-solvent is selected from the group consisting of isopropyl myristate and isopropyl palmitate, and wherein said gelling agent is polyoxyl 40 stearate.
11 - 20 . (canceled)
21 . A method of treating a disease or disorder associated with human papilloma virus in a human patient, the method comprising administering to the skin of a human patient a sensitizing dose of about 0.4% (w/w) DPCP, followed by a challenge dose of about 0.04% (w/w) DPCP at 14 days and then weekly challenge doses of 0.04% (w/w) DPCP for at least 6 weeks.
22 . A method of treating a disease or disorder associated with human papilloma virus in a human patient, the method comprising administering to the skin of a human patient a sensitizing dose of about 0.4% (w/w) DPCP, followed by a challenge dose of about 0.04% (w/w) DPCP at 14 days and then biweekly challenge doses of 0.04% (w/w) DPCP for at least 6 weeks.
23 - 25 . (canceled)